<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02959593</url>
  </required_header>
  <id_info>
    <org_study_id>1602760177</org_study_id>
    <nct_id>NCT02959593</nct_id>
  </id_info>
  <brief_title>The Effects of Visior on Ocular Hemodynamics</brief_title>
  <official_title>The Effects of Visior on Ocular Hemodynamics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Visior Technologies Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Indiana University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Visior Technologies Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the relationship between the affects of viewing commercially available content
      through the VISIOR video goggles and ocular blood flow in glaucoma patients and healthy
      subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To determine if glaucoma patients and healthy subject experience any alteration in localized
      retinal blood flow after retinal stimulation by viewing commercially available content
      through the VISIOR video goggles.

      Both groups will undergo measurements of arterial blood pressure, cardiac pulse (heart rate),
      intraocular pressure, and retinal blood flow using Heidelberg retinal flowmetry (Heidelberg
      Engineering, Heidelberg, Germany) at baseline and then ten minutes, thirty minutes, and sixty
      minutes after viewing commercially available content through the VISIOR video goggles for
      thirty minutes.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>retinal capillary blood flow</measure>
    <time_frame>1 day</time_frame>
    <description>retinal capillary blood flow in arbitrary units</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">35</enrollment>
  <condition>Primary Open Angle Glaucoma</condition>
  <arm_group>
    <arm_group_label>Glaucoma patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>To view commercially available content through the VISIOR video goggles for thirty minutes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>To view commercially available content through the VISIOR video goggles for thirty minutes.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>VISIOR video goggles</intervention_name>
    <description>View commercially available content through the VISIOR video goggles continuously for thirty minutes.</description>
    <arm_group_label>Glaucoma patients</arm_group_label>
    <arm_group_label>Healthy subjects</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with open-angle glaucoma 30 years or older, free from other ophthalmic
             disease, free from diabetes, beta agonists and uncontrolled blood pressure.

        Exclusion Criteria:

          -  Women who are pregnant or lactating or who plan to become pregnant (self reporting);
             smoker during last ten years (self reporting); systemic diseases that may interfere
             with blood flow measurements or wearing the goggles.

          -  In addition, 10 healthy subjects, age 18 or older, free from eye disease will be
             enrolled. Identical exclusion criteria apply to this healthy group. Identical
             procedures apply to this group, which only differs by ocular health status.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alon Harris, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Indiana University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Eugene and Marilyn Glick Eye Institute, Department of Ophthalmology, Indiana School of Medicine</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brent Siesky, PhD</last_name>
      <phone>317-278-0177</phone>
    </contact>
    <investigator>
      <last_name>Alon Harris, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 2016</study_first_submitted>
  <study_first_submitted_qc>November 7, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 9, 2016</study_first_posted>
  <last_update_submitted>November 7, 2016</last_update_submitted>
  <last_update_submitted_qc>November 7, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 9, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Primary open-angle glaucoma</keyword>
  <keyword>retinal capillary blood flow</keyword>
  <keyword>visual stimulation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

